Investigational drug · Phase 2
CTAP101
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for CKD Stage 3, CKD Stage 4, Secondary Hyperparathyroidism.
Phase 2Last checked: Nov 19, 2026Latest source record: Aug 20, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
12
Any phase or sponsor naming "CTAP101"
First trial start
2026
Aug 5, 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "CTAP101", any sponsor or status.
Conditions studied
As listed on its trial records.
- CKD Stage 3
- CKD Stage 4
- Secondary Hyperparathyroidism
- VDI
Approved drugs for the same conditions: Endocrinology and women's health
Largest trials
Live from ClinicalTrials.gov: studies naming "CTAP101" as an intervention, largest first.
- Extension Study of CTAP101-CL-3001 or CTAP101-CL-3002Pivotal-lookingCompleted
OPKO Health, Inc.Industry
NCT02282813 · 298 participants · Start Apr 2013 · Primary completion May 2015
Drug: CTAP101 Capsules; Calcitriol and 2 more · For: Chronic Kidney Disease; Hyperparathyroidism, Secondary; Vitamin D Deficiency
- Safety and Efficacy of CTAP101 to Treat Secondary Hyperparathyroidism in Stage 3 or 4 CKD and Vitamin D InsufficiencyPivotal-lookingCompleted
OPKO IP Holdings II, Inc.Industry
NCT01704079 · 216 participants · Start Nov 2012 · Primary completion Aug 2014
Drug: CTAP101 30 μg capsules · For: Chronic Kidney Disease; Hyperparathyroidism, Secondary; Vitamin D Deficiency
Sites: Bannockburn, Illinois
- Safety and Efficacy of CTAP101 to Treat Secondary Hyperparathyroidism in Stage 3 or 4 CKD and Vitamin D InsufficiencyPivotal-lookingCompleted
OPKO IP Holdings II, Inc.Industry
NCT01651000 · 213 participants · Start Sep 2012 · Primary completion Jul 2014
Drug: CTAP101 30 μg capsules · For: Chronic Kidney Disease; Hyperparathyroidism, Secondary; Vitamin D Deficiency
Sites: Bannockburn, Illinois
- Safety and Efficacy of Rayaldee for Treating Mild to Moderate COVID-19Pivotal-lookingCompleted
OPKO Health, Inc.Industry
NCT04551911 · 171 participants · Start Nov 2, 2020 · Primary completion Oct 8, 2021
Drug: Rayaldee; Placebo · For: COVID-19; Coronavirus; SARS-CoV2 Infection
Sites: San Francisco, California; Miami, Florida; Evanston, Illinois · 10 sites in all
- Safety/Efficacy Study of CTAP101 in Chronic Kidney Disease Subjects With Secondary Hyperparathyroidism (SHPT)Pivotal-lookingCompleted
OPKO Health, Inc.Industry
NCT01219855 · 78 participants · Start Oct 2010 · Primary completion Nov 2011
Drug: Cohort 1 CTAP101 Capsules- 60µg; Cohort 1 CTAP101 Capsules - 90µg and 3 more · For: Chronic Kidney Disease; Secondary Hyperparathyroidism; Vitamin D Insufficiency
Sites: Bannockburn, Illinois
OPKO Health, Inc.Industry
NCT03588884 · 69 participants · Start Jun 8, 2018 · Primary completion Apr 24, 2020
Drug: Calcifediol Oral Capsule; Calcifediol Oral Product and 2 more · For: Secondary Hyperparathyroidism Due to Renal Causes; Vitamin D Insufficiency; CKD Stage 3 and 1 more
Sites: Garden Grove, California; Chicago, Illinois; West Bend, Wisconsin
OPKO Health, Inc.Industry
NCT03660800 · 67 participants · Start Aug 20, 2018 · Primary completion Oct 24, 2018
Drug: CTAP101 Capsules · For: Vitamin D Insufficiency; Secondary Hyperparathyroidism
Sites: Cypress, California
- Safety, Efficacy, PK and PD of CTAP101 (Calcifediol) ER Capsules for SHPT in HD Patients VDITerminated
OPKO Health, Inc.Industry
NCT03602261 · 44 participants · Start Jul 9, 2018 · Primary completion Feb 24, 2021
Drug: Calcifediol Oral Capsule; Placebo oral capsule · For: Secondary Hyperparathyroidism Due to Renal Causes; Chronic Kidney Diseases; Vitamin D Deficiency and 1 more
Sites: Peoria, Arizona; Phoenix, Arizona; Cypress, California · 18 sites in all
OPKO Health, Inc.Industry
NCT07494045 · 40 participants (planned) · Start Aug 5, 2026 · Primary completion Oct 2027
Drug: CTAP101 · For: CKD Stage 3; CKD Stage 4; Secondary Hyperparathyroidism and 1 more
Sites: Kansas City, Missouri; Columbus, Ohio; Philadelphia, Pennsylvania · 5 sites in all
OPKO Health, Inc.Industry
NCT02274623 · 33 participants · Start Dec 2014 · Primary completion Feb 27, 2017
Drug: CTAP101 Capsules · For: Breast Cancer; Prostate Cancer; Bone Neoplasms and 2 more
Sites: Long Beach, California; Miami, Florida; Evergreen Park, Illinois · 6 sites in all
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.